Skip to main content
  • MITRAL Trial Shows MViV, MViR, ViMAC Are Reasonable Treatment Options in High-Risk MR Patients

    Heart failure (HF) symptoms and quality of life can be improved by use of the Sapien 3 aortic balloon-expandable transcatheter heart valve (THV) in patients undergoing transcatheter mitral valve-in-valve (MViV), valve-in-ring (MViR) and valve-in-mitral annular calcifications (ViMAC), particularly MViV, a new investigation shows.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details